Skip to main content
. Author manuscript; available in PMC: 2018 Mar 27.
Published in final edited form as: Nature. 2017 Aug 7;548(7669):537–542. doi: 10.1038/nature23477

Figure 4. Validation of top candidate genes across cancers.

Figure 4

a, Schematic of the array validation strategy for top candidates from the pooled 2CT-CRISPR screen to test generalization across melanomas, MHC class I antigens and other (non-melanoma) cancer. b, Survival of HLA-A*02+ NY-ESO-1+ A375 cells edited with individual sgRNAs (2–4 per gene) after co-culture with ESO T cells at E:T ratio of 0.5. n = 3 biological replicates per sgRNA. c, Shared and unique genes essential for EFT in Mel624 and A375 melanoma cells. d, Survival of HLA-A*02+ NY-ESO-1+ renal cell carcinoma 2245R cells edited with individual sgRNAs (4 per gene) after co-culture with ESO T cells at E:T ratio of 0.5 in 2CT assay. n = 4 biological replicates per sgRNA. b–d, P-value calculated for positively enriched gene-targeting sgRNAs compared to control sgRNA by Student’s t-test. Data representative of at least two independent experiments.